FGFR2 and gastric neoplasm: The reported prevalences of FGFR2 amplification and overexpression in gastric tumors vary: amplification was observed in 11.5% (7/61) of cases in one cohort [32], while overexpression of FGFR2 has been observed in 16.2% (612/3782) of cases (20), going as high as 42% (73/173) in one cohort [20,26,33].